BOVOLENTA, Matteo
 Distribuzione geografica
Continente #
NA - Nord America 4.198
EU - Europa 1.634
AS - Asia 716
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 3
SA - Sud America 2
Totale 6.559
Nazione #
US - Stati Uniti d'America 4.190
PL - Polonia 564
CN - Cina 359
IT - Italia 297
DE - Germania 208
UA - Ucraina 173
TR - Turchia 141
SG - Singapore 132
GB - Regno Unito 120
SE - Svezia 104
FI - Finlandia 55
ID - Indonesia 43
BE - Belgio 33
FR - Francia 22
RU - Federazione Russa 14
VN - Vietnam 14
HK - Hong Kong 13
NL - Olanda 12
CZ - Repubblica Ceca 9
IE - Irlanda 8
CA - Canada 7
IN - India 7
EU - Europa 5
HR - Croazia 4
CH - Svizzera 3
ES - Italia 3
AU - Australia 2
IR - Iran 2
RO - Romania 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BG - Bulgaria 1
BR - Brasile 1
CL - Cile 1
GL - Groenlandia 1
JP - Giappone 1
KR - Corea 1
MM - Myanmar 1
MN - Mongolia 1
MY - Malesia 1
NZ - Nuova Zelanda 1
RS - Serbia 1
Totale 6.559
Città #
Warsaw 564
Woodbridge 554
Fairfield 515
Ann Arbor 386
Houston 327
Chandler 322
Ashburn 249
Jacksonville 218
Seattle 211
Wilmington 200
Cambridge 174
Ferrara 116
Singapore 104
Izmir 96
Nanjing 83
New York 61
Princeton 60
Beijing 53
Milan 52
San Diego 48
Shanghai 48
Boardman 45
Jakarta 41
Bremen 37
Dearborn 30
Brussels 28
Munich 26
Nanchang 23
Falls Church 22
Tianjin 20
Shenyang 19
Los Angeles 18
Kunming 16
Santa Clara 15
Bologna 13
Des Moines 13
Hebei 13
Dong Ket 12
Helsinki 12
Hong Kong 12
Redwood City 12
Changsha 11
London 11
Auburn Hills 10
Jinan 10
San Mateo 10
Washington 10
Brno 8
Mountain View 8
Norwalk 7
Absecon 6
Addison 6
Hangzhou 6
Rome 6
Hefei 5
Jiaxing 5
Ningbo 5
Zhengzhou 5
Ferrara di Monte Baldo 4
Guangzhou 4
Leawood 4
Leiden 4
Menlo Park 4
Modena 4
Shenzhen 4
Taizhou 4
Augusta 3
Chicago 3
Clifton 3
Dublin 3
Evanston 3
Genova 3
Indiana 3
Monmouth Junction 3
Napoli 3
Phoenix 3
Redmond 3
Tappahannock 3
Verona 3
Wuhan 3
Balasore 2
Borgo Val di Taro 2
Brescia 2
Changchun 2
Chengdu 2
Collecorvino 2
Fort Worth 2
Fremont 2
Genoa 2
Guarda Veneta 2
Haikou 2
Hanoi 2
Hasselt 2
Hounslow 2
Lainate 2
Lanzhou 2
Lausanne 2
Lawrenceville 2
New Bedfont 2
Orange 2
Totale 5.111
Nome #
Deep RNA profiling identified CLOCK and molecular clock genes as pathophysiological signatures in collagen VI myopathy 327
Correction of the Exon 2 Duplication in DMD Myoblasts by a Single CRISPR/Cas9 System 305
Transcriptional and epigenetic analyses of the DMD locus reveal novel cis-acting DNA elements that govern muscle dystrophin expression 299
C6orf10 low-frequency and rare variants in italian multiple sclerosis patients 184
Exploring Splicing-Switching Molecules For Seckel Syndrome Therapy 183
Crispr/Cas9-based COL7A1 editing for recessive dystrophic epidermolysis bullosa 175
Fo ATP synthase C subunit serum levels in patients with ST-segment Elevation Myocardial Infarction: Preliminary findings 159
null 155
Omics approach and novel biostatistic tools identified RPL3L as potential genetic modifier of clinical severity in female carriers of Duchenne muscle dystrophy 151
An engineered tale-transcription factor rescues transcription of factor VII impaired by promoter mutations and enhances its endogenous expression in hepatocytes 150
Transcriptomics analysis in collagen VI myopathy: Role of circadian genes using novel fluidic card tools 148
An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis 148
Genetic characterization in symptomatic female DMD carriers: lack of relationship between X-inactivation, transcriptional DMD allele balancing and phenotype 144
Macrophages: a minimally invasive tool for monitoring collagen VI myopathies 143
Exon skipping-mediated dystrophin reading frame restoration for small mutations 141
Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse 140
Antisense-Induced Messenger Depletion Corrects a COL6A2 Dominant Mutation in Ullrich Myopathy 132
null 131
The absence of dystrophin brain isoform expression in healthy human heart ventricles explains the pathogenesis of 5 ' X-linked dilated cardiomyopathy 130
The DMD Locus Harbours Multiple Long Non-Coding RNAs Which Orchestrate and Control Transcription of Muscle Dystrophin mRNA Isoforms 127
Identification of a deep intronic mutation in the COL6A2 gene by a novel custom oligonucleotide CGH array designed to explore allelic and genetic heterogeneity in collagen VI-related myopathies 126
A novel custom high density-comparative genomic hybridization array detects common rearrangements as well as deep intronic mutations in dystrophinopathies 119
D.P.12 Whole exome sequencing and RNAseq in a Duchenne-like female with no dystrophin mutations: Search for dystrophin gene modifiers 118
Correction of duplications in the DMD gene by a CRISPR/Cas9 approach 118
Rapid, comprehensive analysis of the dystrophin transcript by a custom micro-fluidic exome array 116
D.P.9 Whole exome sequencing filtered by novel candidate genes as tool for gene discovery in a recessive family with Parkinson and ataxia 115
null 113
G.P.12.06 A comprehensive molecular characterisation of dystrophinopathies 112
Autosomal recessive Bethlem myopathy 111
Transcriptional behavior of DMD gene duplications in DMD/BMD males 110
G.P.15 Whole transcriptome expression profiling in COL6a1 null mice shows deregulation of circadian clock genes as exploratory COL6 myopathies biomarkers 108
D.P.7 Whole exome sequencing as genetic diagnostic tool in myofibrillar myopathies 107
Identification and characterization of novel collagen VI non-canonical splicing mutations causing ullrich congenital muscular dystrophy 107
Antisense modulation of both exonic and intronic splicing motifs induces skipping of a DMD pseudo-exon responsible for X-linked dilated cardiomyopathy 105
Tailoring the CRISPR system to transactivate coagulation gene promoters in normal and mutated contexts 104
Prenatal diagnosis of Duchenne muscular dystrophy by comparative genomic hybridization 103
Custom CGH array profiling of copy number variations (CNVs) on chromosome 6p21.32 (HLA locus) in patients with venous malformations associated with multiple sclerosis 102
P1.19 Whole genetic and protein characterisation in DMD symptomatic female carriers excludes correlation with X-inactivation and transcriptional DMD allele balancing 99
Correction of duplications in the DMD gene by a CRISPR/Cas9 approach 97
EM.P.4.07 Autosomal recessive Bethlem myopathy 87
null 86
T.P.2.07 The systemic administration of a low dose of 2OMePS-AON combined with novel cationic polymethylmethacrylate nanoparticles induces the rescue of dystrophin expression in the mdx murine model 86
PLC-beta2 monitors the drug-induced release of differentiation blockade in tumoral myeloid precursors 81
Ex Vivo COL7A1 Correction for Recessive Dystrophic Epidermolysis Bullosa Using CRISPR/Cas9 and Homology-Directed Repair 75
Studio di CNVs nel locus HLA (6p21.32) mediante Array CGH in pazienti con Sclerosi Multipla e malformazioni venose 69
Exploiting The CRISPR/CAS9 System to Study Alternative Splicing In Vivo: Application to titin 62
CRISPR activation on coagulation F7 or F8 promoters potentiate trascriptional activity in the normal and mutated gene context 58
Transcriptional enhancement as therapeutic approach of coagulation factor VII promoter mutations 57
MOLECULAR MECHANISMS AND THERAPEUTIC APROACHES FOR RESTORATION OF mRNA TRANSCRIPTION, MATURATION AND TRANSLATION IN INHERITED COAGULATION FACTOR DEFICIENCIES 56
A naturally occurring mutation in ATP synthase subunit c is associated with increased damage following hypoxia/reoxygenation in STEMI patients 53
Antisense oligonucleotides conjugated with lipophilic compounds: synthesis and in vitro evaluation of exon skipping in duchenne muscular dystrophy 48
Engineered transcription factors (TALE-TF) as potential therapeutic strategy for coagulation factor deficiencies caused by promoter mutations 46
Conjugates of oligonucleotides and bile acids and their derivatives for pharmaceutical active molecules delivery 39
Translation from a DMD exon 5 IRES results in a functional dystrophin isoform that attenuates dystrophinopathy in humans and mice 30
Synthesis and exon‐skipping properties of a 3′‐ursodeoxycholic acid‐conjugated oligonucleotide targeting dmd pre‐mrna: Pre‐synthetic versus post‐ synthetic approach 27
Chromatin configuration, RNA and protein studies identified novel DNA elements that influence the dystrophin transcription dynamics 26
Nanoparticle-Mediated Delivery of Antisense Oligoribonucleotides Allows Restoration of Dystrophin Expression in the mdx Mouse 24
A new rat model for Duchenne muscular dystrophy generated by CRISPR-induced deletion of Exon 45 24
ncRNAs originating from the dystrophin gene as biomarker for assessing antisense therapy 22
Efficient generation of mouse models with the CRISPR/Cas9 technology 21
Nanoparticles are effective vehicles for systemic delivery of 2 ' OMePS antisense oligonucleotides in exon skipping-mediated dystrophin restoration 17
Pre-trial antisense screening of myogenic cells from boys with Duchenne muscular dystrophy and genomic and transcriptomic biomarkers discovery for treatment monitoring 15
G.P.3.02 In vivo biodistribution of non-viral systems for oligoribonucleotides delivery 15
In Vitro Studies to Evaluate the Intestinal Permeation of an Ursodeoxycholic Acid-Conjugated Oligonucleotide for Duchenne Muscular Dystrophy Treatment 14
Targeted Genome Editing in Spinal Muscular Atrophy 11
Correction of exon 2, exon 2–9 and exons 8–9 duplications in DMD patient myogenic cells by a single CRISPR/Cas9 system 2
Totale 6.713
Categoria #
all - tutte 29.709
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.709


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.068 0 0 0 202 100 182 138 124 112 120 45 45
2020/20211.053 99 69 75 125 53 75 90 99 52 139 121 56
2021/2022746 41 55 47 37 33 35 67 38 31 62 86 214
2022/2023812 75 82 8 111 154 93 52 63 85 11 44 34
2023/2024435 35 47 37 10 35 97 10 30 10 5 12 107
2024/2025241 41 30 158 12 0 0 0 0 0 0 0 0
Totale 6.713